Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

  • STATUS
    Recruiting
  • End date
    Aug 1, 2024
  • participants needed
    60
  • sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
Updated on 14 October 2020
Investigator
Robin R. Eisch, R.N.
Primary Contact
National Institutes of Health Clinical Center (9.7 mi away) Contact

Summary

Background

Mast cells help the body fight disease and heal wounds. People with indolent systemic mastocytosis (ISM) make too many mast cells. This causes pain, tiredness, digestive problems, and other symptoms. Researchers think the drug sarilumab could help.

Objective

To see if sarilumab is a safe and effective treatment for people with ISM.

Eligibility

Adults ages 18-75 with ISM who are enrolled in NIH study 02-I-0277

Design

Participants will be screened with:

  • Physical exam
  • Medical history
  • Blood and urine tests
  • Questionnaires
  • Bone marrow removed by a needle inserted into the hip bone
  • Ultrasound of the abdomen
  • Photographs of the skin

Participants will repeat some screening tests at study visits.

Participants will have a baseline visit in the hospital for 3 days. They will:

  • Be assigned to get either the study drug or a placebo. They will not know which one they get.
  • Have a skin punch biopsy: An instrument will remove a small piece of skin.
  • Get their first drug dose injected under their skin

Participants will keep a side effect and medication diary during the study.

Participants will visit the clinic to get a drug dose every 2 weeks, for a total of 8 doses.

Participants will have a visit 2 weeks after their final dose. It will last up to 2 days.

Participants will have another visit 12 weeks later.

Participants may then continue this study for 1 more year. Those who continue will get sarilumab, even if they previously got the placebo, every 2 weeks. They will have visits every 6 weeks, and then every 3 months.

Description

Systemic mastocytosis is a disorder caused by clonal mast cell proliferation and release of mast cell mediators including tryptase. As a result, mast cell numbers may increase and affect target organs including the dermis (maculopapular cutaneous mastocytosis/urticaria pigmentosa, flushing), gastrointestinal tract (abdominal pain, diarrhea), skeletal system (osteoporosis), hematological system (anemia, thrombocytopenia), and spleen and liver (organomegaly). Patients with indolent (non-aggressive) systemic mastocytosis (ISM) are not candidates for cytoreductive therapy and are generally treated with symptomatic therapy that only partly decreases symptoms. There is, however, a documented association between severity of mastocytosis and elevated serum levels of interleukin (IL)-6. Furthermore, mast cells have been shown to double their rate of division and exhibit increased reactivity and release of mediators when cultured in the presence of IL-6. In addition, in an animal model of mastocytosis, anti-IL-6 has been shown to slow disease progression. In this study, adults with ISM will thus be randomized and treated with sarilumab, a recombinant monoclonal antibody directed against the IL-6 receptor, or receive placebo. Sarilumab is marketed in the United States as Kevzara (Sanofi/Genzyme [Cambridge, MA, USA ]) and is approved by the Food and Drug Administration for the treatment of rheumatoid arthritis. Binding of sarilumab to the IL-6 receptor inhibits IL-6-associated human mast cell signaling and proliferation with a resultant decrease in proliferation and reactivity (decreased mediator release), and therefore is a rational choice for the treatment of ISM.

In this study, participants will be randomized with approximately half of the participants receiving study drug, which will be administered at 200 mg via subcutaneous (SC) injection once every 2 weeks (Q2W) for a total of 16 weeks. The other participants will receive a placebo administered via SC injection Q2W for 16 weeks. Participants will return for a follow-up visit 2 weeks after the final dose (treatment peak), and then again 12 weeks later. Evaluations at study visits will include quality of life and symptom assessments and measurement of serum tryptase levels. Bone marrow examination will be performed at the onset and conclusion of the study. After the week 28 visit, all participants will have the option to continue sarilumab for 52 more weeks, at 200 mg administered via SC injections. Participants will continue to be monitored on a regular basis for safety concerns, as instructed in the study drug s package insert.

Details
Treatment Placebo, Sarilumab
Clinical Study IdentifierNCT03770273
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Last Modified on14 October 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 74 yrs?
Gender: Male or Female
Do you have Systemic mastocytosis?
Participants must meet all of the following criteria to be enrolled in this
study
Male or female participant greater than or equal to 18 and < 75 years of age at screening
Enrolled on NIAID protocol 02-I-0277
Documented pathologic diagnosis of ISM
MC-QoL score of at least 25% (which suggests participant is at least somewhat affected by all McQoL questions)
Willing and able to undergo a bone marrow biopsy and aspirate
Absolute neutrophil count (ANC) greater than or equal to 2000/mL
Hemoglobin greater than or equal to 12.0 g/dL (males), greater than or equal to 11 g/dL (females)
Platelet count greater than or equal to 150,000/microliters
Alanine transaminase (ALT) and aspartate transaminase (AST) < 1.5 times the upper limit of normal (ULN)
Willing to allow storage of blood and bone marrow for future use in medical research
Willing to allow genetic testing on biospecimens
Able to provide informed consent
Participants who can become pregnant must agree to use adequate contraception when engaging in sexual activities that can result in pregnancy. Adequate contraception must be used consistently, beginning at least 1 month before the beginning of dosing and lasting until 3 months after the final dose of study drug. Acceptable methods of contraception include the following
Hormonal contraception (non-oral only)
Male or female condom with spermicide
Diaphragm or cervical cap with a spermicide
Intrauterine device

Exclusion Criteria

Individuals meeting any of the following criteria will be excluded from study
participation
Any abnormality that would be scored as a Grade 4 toxicity on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Only clinically significant lab results will deem the subject ineligible
Infected with HIV or has other known immunodeficiency
Has an active infection, including localized infection
Active diverticulitis
Active or chronic viral hepatitis
Active or latent tuberculosis
Use of any other anti-IL-6 or anti-IL-6R agent within 1 year prior to the date informed consent was obtained
Use of cytoreductive therapy for mastocytosis within 1 year prior to the date informed consent was obtained
Known lymphoma or advanced and metastatic solid tumors on active therapy (including chemotherapy) within 1 year prior to the date informed consent was obtained
Use of chemotherapy within 1 year prior to the date informed consent was obtained
Receipt of any marketed (eg, omalizumab) or investigational biologic or monoclonal antibody reported to affect mast cell activation within 5 half-lives prior to date informed consent was obtained
Receipt of intravenous (IV) immunoglobulin within 30 days prior to the date informed consent was obtained
Receipt of live attenuated vaccines within 30 days prior to the date informed consent was obtained
History of alcohol or drug/abuse within 12 months prior to date informed consent was obtained
Is allergic to any component of the sarilumab formulation
Pregnant or breastfeeding
Any condition that, in the opinion of the investigator, contraindicates participation in this study
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.
Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more
Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more
Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet